이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Merck 과거 수익 실적

과거 기준 확인 0/6

Merck의 수입은 연평균 -3.8%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 10.5%의 비율로 증가했습니다. 매출은 연평균 8.8%의 비율로 증가해 왔습니다. Merck의 자기자본이익률은 5.7%이고 순이익률은 3.8%입니다.

주요 정보

-3.8%

수익 성장률

-3.4%

EPS 성장률

Pharmaceuticals 산업 성장	12.4%
매출 성장률	8.8%
자기자본 수익률	5.7%
순이익	3.8%
다음 실적 업데이트	30 Jul 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

수익 및 비용 분석

Merck 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

BASE:MRKD 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	61,403	2,306	9,839	18,592
31 Dec 23	60,115	365	9,884	18,342
30 Sep 23	59,315	4,608	10,226	12,481
30 Jun 23	58,311	3,111	9,934	12,685
31 Mar 23	57,869	13,030	9,851	12,433
31 Dec 22	59,283	14,519	9,669	11,918
30 Sep 22	58,974	15,322	10,119	11,923
30 Jun 22	57,169	16,641	9,776	10,940
31 Mar 22	53,978	13,910	9,489	10,515
31 Dec 21	48,704	12,345	9,403	11,942
30 Sep 21	46,131	5,908	9,260	10,725
30 Jun 21	43,906	3,665	8,845	10,678
31 Mar 21	41,857	4,793	8,669	10,339
31 Dec 20	41,518	4,519	8,569	10,564
30 Sep 20	42,438	9,492	8,812	9,079
30 Jun 20	43,906	9,070	9,200	8,818
31 Mar 20	46,312	9,399	9,700	8,990
31 Dec 19	39,121	5,690	8,829	8,594
30 Sep 19	45,970	9,314	9,604	8,489
30 Jun 19	44,367	9,362	9,586	7,997
31 Mar 19	43,073	8,399	9,467	8,084
31 Dec 18	42,294	6,220	9,587	9,254
30 Sep 18	41,729	3,347	9,541	9,251
30 Jun 18	41,259	1,341	9,554	11,680
31 Mar 18	40,725	1,579	9,449	11,182
31 Dec 17	40,122	2,394	9,560	9,845
30 Sep 17	39,804	2,845	9,615	9,427
30 Jun 17	40,016	5,086	9,612	6,916
31 Mar 17	39,929	4,346	9,713	7,035
31 Dec 16	39,807	3,920	9,313	6,921
30 Sep 16	39,907	5,492	9,193	6,849
30 Jun 16	39,444	5,133	9,312	6,828
31 Mar 16	39,385	4,614	9,776	6,518
31 Dec 15	39,498	4,442	9,799	6,613
30 Sep 15	39,765	10,781	10,262	6,727
30 Jun 15	40,249	9,850	10,756	6,644
31 Mar 15	41,398	11,168	10,818	6,685
31 Dec 14	42,237	11,920	11,172	6,532
30 Sep 14	43,075	5,385	11,501	6,435
30 Jun 14	43,550	5,614	11,304	6,544
31 Mar 14	43,626	4,516	11,511	6,774
31 Dec 13	44,033	4,404	11,672	7,123
30 Sep 13	44,450	4,531	12,084	7,563

양질의 수익: MRKD 에는 $12.7B 큰 일회성 손실이 있습니다. $12.7B 은 지난 12개월 간의 재무 결과에 31st March, 2024 까지 영향을 미쳤습니다.

이익 마진 증가: MRKD 의 현재 순이익 이익률 (3.8%) 작년보다 낮습니다 (22.5%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: MRKD 의 수입은 지난 5년 동안 매년 3.8% 씩 감소했습니다.

성장 가속화: MRKD 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: MRKD 은 지난 1년 동안 마이너스 수익 성장( -82.3% )을 기록하여 Pharmaceuticals 업계 평균( 6.4% ).

Merck 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Merck Receives Positive EU CHMP Opinion for WINREVAIR (Sotatercept) in Pulmonary Arterial Hypertension (PAH)

CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma

Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Eyebiotech Limited for $3 billion.

Merck Declares Dividend for the Third Quarter of 2024, Payable on July 8, 2024

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기